StanleyBlack&Decker

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ) Stanley Black & Decker

Chemwatch Hazard Alert Code: 4

Issue Date: **06/12/2024** Print Date: **06/18/2024** L.GHS.AUS.EN.E

Version No: 3.1
Safety Data Sheet according to Work Health and Safety Regulations (Hazardous Chemicals) 2023 and ADG requirements

SECTION 1 Identification of the substance / mixture and of the company / undertaking

Product name	Lithium-lon Battery Packs (less than or equal to 100 Watt Hours) (NZ)			
Chemical Name	Not Applicable			
Synonyms	Detachable Battery Packs:; Black & Decker:; (7 Volt) - VPX0111; (10.8 Volt) - BL1110, BL1310, BL1510, BL1512, BK1512; (14.4 Volt) - A1114L, A1514L, BL1114, BL1314, BL1514; (18 Volt) - A1518L, A1118L, LB018, BL1118, BL1318, BL1518, BL2018; (36 Volt) - BL1336, BL1536, BL2036; (18 Volt/54 Volt) - BL1554; DEWALT.; (8 Volt) - DCB080; (10.8 Volt) - DCB121, DCB123, DCB125, DCB127; (14.4 Volt) - DC9140, DE9140, DE9141, DC9144, DCB140, DCB141, DCB141, DCB143, DCB143, DCB184, DCB185, DCB188, DCB181, DC9180,			
Proper shipping name	LITHIUM ION BATTERIES CONTAINED IN EQUIPMENT or LITHIUM ION BATTERIES PACKED WITH EQUIPMENT (including lithium ion polymer batteries)			
Chemical formula	Not Applicable			
Other means of identification	Not Available			

Relevant identified uses of the substance or mixture and uses advised against

Relevant identif	ied uses
------------------	----------

Chemwatch: 5670-40

Battery. To power Stanley Black & Decker products. Note: Hazard statement relates to battery contents. Potential for exposure should not exist unless the battery leaks, is exposed to high temperatures or is mechanically, physically or electrically abused. Use according to manufacturer's directions.

Details of the manufacturer or supplier of the safety data sheet

Registered company name	Stanley Black & Decker	Stanley Black & Decker (New Zealand) Ltd
Address	Level 2 / 810 Whitehorse Road Box Hill VIC 3128 Australia	39 Business Parade North Highbrook East Tamaki Heights Auckland 2013 New Zealand
Telephone	1800 338 002	0800 339 258
Fax	1800 080 898	09 273 3992
Website	www.stanleyblackanddecker.com	www.stanleyblackandecker.com
Email anzcustfeedback@sbdinc.com		nzorder@sbdinc.com

Emergency telephone number

Association / Organisation	Not Available	Not Available	CHEMWATCH EMERGENCY RESPONSE (24/7)
Emergency telephone numbers	1800 039 008	+800 2436 2255	+61 1800 951 288
Other emergency telephone numbers	+612 9186 1132	Not Available	+61 3 9573 3188

Once connected and if the message is not in your preferred language then please dial 01

SECTION 2 Hazards identification

Classification of the substance or mixture

Poisons Schedule	Not Applicable		
Classification ^[1]	Acute Toxicity (Oral) Category 1, Aspiration Hazard Category 1, Acute Toxicity (Dermal) Category 4, Skin Corrosion/Irritation Category 1A, Sensitisation (Skin) Category 1, Serious Eye Damage/Eye Irritation Category 1, Acute Toxicity (Inhalation) Category 2, Sensitisation (Respiratory) Category 1, Specific Target Organ Toxicity - Single Exposure (Respiratory Tract Irritation) Category 3, Germ Cell Mutagenicity Category 1A, Carcinogenicity Category 1A, Reproductive Toxicity Category 2, Specific Target Organ Toxicity - Repeated Exposure Category 1, Hazardous to the Aquatic Environment Long-Term Hazard Category 1		
Legend:	1. Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI		

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

Label elements

Hazard pictogram(s)









Signal word Danger

Hazard statement(s)

H300	Fatal if swallowed.		
H304	May be fatal if swallowed and enters airways.		
H312	armful in contact with skin.		
H314	auses severe skin burns and eye damage.		
H317	May cause an allergic skin reaction.		
H330	Fatal if inhaled.		
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.		
H335	May cause respiratory irritation.		
H340	May cause genetic defects.		
H350	May cause cancer.		
H361fd	Suspected of damaging fertility. Suspected of damaging the unborn child.		
H372	Causes damage to organs through prolonged or repeated exposure.		
H410	Very toxic to aquatic life with long lasting effects.		

Precautionary statement(s) Prevention

P201	Obtain special instructions before use.	
P260	Oo not breathe dust/fume.	
P264	Wash all exposed external body areas thoroughly after handling.	
P270	Do not eat, drink or smoke when using this product.	
P271	Use only outdoors or in a well-ventilated area.	
P280	Wear protective gloves, protective clothing, eye protection and face protection.	
P284	[In case of inadequate ventilation] wear respiratory protection.	
P273	Avoid release to the environment.	
P272	Contaminated work clothing should not be allowed out of the workplace.	

Precautionary statement(s) Response

P301+P310	IF SWALLOWED: Immediately call a POISON CENTER/doctor/physician/first aider.		
P301+P330+P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. If more than 15 mins from Doctor, INDUCE VOMITING (if conscious).		
P303+P361+P353	IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water [or shower].		
P304+P340	IF INHALED: Remove person to fresh air and keep comfortable for breathing.		
P305+P351+P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.		
P308+P313	IF exposed or concerned: Get medical advice/ attention.		
P342+P311	If experiencing respiratory symptoms: Call a POISON CENTER/doctor/physician/first aider.		
P302+P352	IF ON SKIN: Wash with plenty of water and soap.		
P363	Wash contaminated clothing before reuse.		
P333+P313	If skin irritation or rash occurs: Get medical advice/attention.		
P362+P364	Take off contaminated clothing and wash it before reuse.		
P391	Collect spillage.		

Precautionary statement(s) Storage

P403+P233	Store in a well-ventilated place. Keep container tightly closed.	
P405	Store locked up.	

Precautionary statement(s) Disposal

P501 Dispose of contents/container to authorised hazardous or special waste collection point in accordance with any local regulation.

SECTION 3 Composition / information on ingredients

Substances

See section below for composition of Mixtures

Mixtures

CAS No	%[weight]	Name
Not Available		sealed can containing,

Chemwatch: 5670-40 Page 3 of 16

Version No. 3.1

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

CAS No	%[weight]	Name
7440-50-8	10-30	copper
Not Available	10-14	Mixed Organic carbonates
65997-19-5	7-13	Stainless Steel
7429-90-5	7-13	aluminium
12057-17-9	5-10	lithium manganate
12190-79-3	5-10	lithium cobaltate
346417-97-8	5-10	lithium nickel manganese cobalt oxide
193214-24-3	5-10	lithium nickel cobalt aluminium oxide
7440-02-0	3-7	nickel
21324-40-3	1-3	lithium fluorophosphate
Legend:	Classified by Chemwatch; 2. Classification drawn from HCIS; 3. Classification drawn from Regulation (EU) No 1272/2008 - Annex VI; 4. Classification drawn from C&L * EU IOELVs available	

SECTION 4 First aid measures

Description of first aid measures

Eye Contact	If battery is leaking and material contacts the eye. If this product comes in contact with the eyes: Immediately hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes. Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. Seek medical attention without delay.		
Skin Contact	If battery is leaking and material contacts the skin. Remove all contaminated clothing, including footwear. Wash thoroughly all affected areas with water and soap. Seek medical attention if swelling/redness/blistering or irritation occurs.		
Inhalation	If battery is leaking, contents may be irritating to respiratory passages. Remove patient to fresh air and seek medical attention.		
Ingestion	▶ For advice, contact a Poisons Information Centre or a doctor.		

Indication of any immediate medical attention and special treatment needed

Following acute or short term repeated exposure to hydrofluoric acid:

- Subcutaneous injections of Calcium Gluconate may be necessary around the burnt area. Continued application of Calcium Gluconate Gel or subcutaneous Calcium Gluconate should then continue for 3-4 days at a frequency of 4-6 times per day. If a "burning" sensation recurs, apply more frequently.
- > Systemic effects of extensive hydrofluoric acid burns include renal damage, hypocalcaemia and consequent cardiac arrhythmias. Monitor haematological, respiratory, renal, cardiac and electrolyte status at least daily. Tests should include FBE, blood gases, chest X-ray, creatinine and electrolytes, urine output, Ca ions, Mg ions and phosphate ions. Continuous ECG monitoring may be required.
- Where serum calcium is low, or clinical, or ECG signs of hypocalcaemia develop, infusions of calcium gluconate, or if less serious, oral Sandocal, should be given. Hydrocortisone 500 mg in a four to six hourly infusion may help.
- Antibiotics should not be given as a routine, but only when indicated.
- ▶ Eye contact pain may be excruciating and 2-3 drops of 0.05% pentocaine hydrochloride may be instilled, followed by further irrigation

BIOLOGICAL EXPOSURE INDEX - BEL

These represent the determinants observed in specimens collected from a healthy worker exposed at the Exposure Standard (ES or TLV):

Determinant Index Sampling Time Comments 1.5% of haemoglobin During or end of shift 1. Methaemoglobin in blood B. NS. SQ

B: Background levels occur in specimens collected from subjects NOT exposed.

NS: Non-specific determinant; Also seen after exposure to other materials

SQ: Semi-quantitative determinant - Interpretation may be ambiguous; should be used as a screening test or confirmatory test.

Clinical effects of lithium intoxication appear to relate to duration of exposure as well as to level.

- Lithium produces a generalised slowing of the electroencephalogram; the anion gap may increase in severe cases. ▶ Emesis (or lavage if the patient is obtunded or convulsing) is indicated for ingestions exceeding 40 mg (Li)/Kg.
- P Overdose may delay absorption; decontamination measures may be more effective several hours after cathartics
- Charcoal is not useful. No clinical data are available to guide the administration of catharsis
- Haemodialysis significantly increases lithium clearance; indications for haemodialysis include patients with serum levels above 4 meq/L.
- There are no antidotes.

[Ellenhorn and Barceloux: Medical Toxicology]

- Chronic exposures to cobalt and its compounds results in the so-called "hard metal pneumoconiosis" amongst industrial workers. The lesions consist of nodular conglomerate shadows in the lungs, together with peribronchial infiltration. The disease may be reversible. The acute form of the disease resembles a hypersensitivity reaction with malaise, cough and wheezing; the chronic form progresses to cor pulmonale.
- Chronic therapeutic administration may cause goiter and reduced thyroid activity.
- An allergic dermatitis, usually confined to elbow flexures, the ankles and sides of the neck, has been described.
- Cobalt cardiomyopathy may be diagnosed early by changes in the final part of the ventricular ECG (repolarisation). In the presence of such disturbances, the changes in carbohydrate metabolism (revealed by the glucose test) are of important diagnostic value.
- Treatment generally consists of a combination of Retabolil (1 injection per week over 4 weeks) and beta-blockers (average dose 60-80 mg Obsidan/24 hr). Potassium salts and diuretics have also proved useful.

BIOLOGICAL EXPOSURE INDEX (BEI)

Sampling time Determinant Comments Index Cobalt in urine End of shift at end of workweek 15 ug/L Cobalt in blood End of shift at end of workweek B SO 1 ug/L

B: Background levels occur in specimens collected from subjects NOT exposed

SQ: Semi-quantitative determinant - Interpretation may be ambiguous; should be used as a screening test or confirmatory test.

Version No: 3.1

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

SECTION 5 Firefighting measures

Extinguishing media

- ▶ There is no restriction on the type of extinguisher which may be used.
- Use extinguishing media suitable for surrounding area.

Special hazards arising from the substrate or mixture

Fire Incompatibility

Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Advice for firefighters	
Fire Fighting	 Alert Fire Brigade and tell them location and nature of hazard. Wear breathing apparatus plus protective gloves in the event of a fire. Prevent, by any means available, spillage from entering drains or water courses. Use fire fighting procedures suitable for surrounding area. DO NOT approach containers suspected to be hot. Cool fire exposed containers with water spray from a protected location. If safe to do so, remove containers from path of fire. Equipment should be thoroughly decontaminated after use. Slight hazard when exposed to heat, flame and oxidisers.
Fire/Explosion Hazard	 Non combustible. Not considered a significant fire risk Heating may cause expansion or decomposition leading to violent rupture of containers. Decomposes on heating and produces toxic fumes of carbon monoxide (CO). May emit acrid smoke and poisonous, corrosive fumes Decomposition may produce toxic fumes of: carbon dioxide (CO2) carbon monoxide (CO2) metal oxides hydrofluoric acid
HAZCHEM	2Y

SECTION 6 Accidental release measures

Personal precautions, protective equipment and emergency procedures

See section 8

Environmental precautions

See section 12

Methods and material for containment and cleaning up

Minor Spills	 Clean up all spills immediately. Secure load if safe to do so. Bundle/collect recoverable product. Collect remaining material in containers with covers for disposal.
Major Spills	 Clean up all spills immediately. Wear protective clothing, safety glasses, dust mask, gloves. Secure load if safe to do so. Bundle/collect recoverable product. Use dry clean up procedures and avoid generating dust. Vacuum up (consider explosion-proof machines designed to be grounded during storage and use). Water may be used to prevent dusting. Collect remaining material in containers with covers for disposal. Flush spill area with water.

Personal Protective Equipment advice is contained in Section 8 of the SDS.

SECTION 7 Handling and storage

Precautions for safe handling	
Safe handling	 Limit all unnecessary personal contact. Wear protective clothing when risk of exposure occurs. Use in a well-ventilated area. Avoid contact with incompatible materials. When handling, DO NOT eat, drink or smoke. Keep containers securely sealed when not in use. Avoid physical damage to containers. Always wash hands with soap and water after handling. Work clothes should be laundered separately. Use good occupational work practice. Observe manufacturer's storage and handling recommendations contained within this SDS. Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
Other information	 Store in original containers. Keep containers securely sealed. Store in a cool, dry, well-ventilated area. Store away from incompatible materials and foodstuff containers. Protect containers against physical damage and check regularly for leaks. Observe manufacturer's storage and handling recommendations contained within this SDS. Store away from incompatible materials. Keep out of reach of children.

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

Suitable container

Storage incompatibility

- ▶ Packaging as recommended by manufacturer.
- Avoid strong bases.Avoid strong acids, acid chlorides, acid anhydrides and chloroformates.
- Avoid reaction with oxidising agents

SECTION 8 Exposure controls / personal protection

Control parameters

Occupational Exposure Limits (OEL)

INGREDIENT DATA

INGREDIENT DATA						
Source	Ingredient	Material name	TWA	STEL	Peak	Notes
Australia Exposure Standards	copper	Copper (fume)	0.2 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	copper	Copper, dusts & mists (as Cu)	1 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	aluminium	Aluminium, pyro powders (as AI)	5 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	aluminium	Aluminium (welding fumes) (as Al)	5 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	aluminium	Aluminium (metal dust)	10 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	lithium manganate	Manganese, dust & compounds (as Mn)	1 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	lithium nickel manganese cobalt oxide	Manganese, dust & compounds (as Mn)	1 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	nickel	Nickel, powder	1 mg/m3	Not Available	Not Available	Not Available
Australia Exposure Standards	nickel	Nickel, metal	1 mg/m3	Not Available	Not Available	Not Available

Emergency Limits

Ingredient	TEEL-1	TEEL-2	TEEL-3
copper	3 mg/m3	33 mg/m3	200 mg/m3
nickel	4.5 mg/m3	50 mg/m3	99 mg/m3
lithium fluorophosphate	7.5 mg/m3	83 mg/m3	500 mg/m3

Ingredient	Original IDLH	Revised IDLH
copper	100 mg/m3	Not Available
Stainless Steel	Not Available	Not Available
aluminium	Not Available	Not Available
lithium manganate	500 mg/m3	Not Available
lithium cobaltate	Not Available	Not Available
lithium nickel manganese cobalt oxide	500 mg/m3 / 10 mg/m3	Not Available
lithium nickel cobalt aluminium oxide	10 mg/m3	Not Available
nickel	10 mg/m3	Not Available
lithium fluorophosphate	Not Available	Not Available

Occupational Exposure Banding

Ingredient	Occupational Exposure Band Rating	Occupational Exposure Band Limit	
Stainless Steel	E	≤ 0.01 mg/m³	
lithium cobaltate	E	≤ 0.01 mg/m³	
lithium nickel cobalt aluminium oxide	D	> 0.01 to ≤ 0.1 mg/m³	
lithium fluorophosphate	E ≤ 0.01 mg/m³		
Notes:	Occupational exposure banding is a process of assigning chemicals into specific categories or bands based on a chemical's potency and the		

adverse health outcomes associated with exposure. The output of this process is an occupational exposure band (OEB), which corresponds to a range of exposure concentrations that are expected to protect worker health.

MATERIAL DATA

Exposure controls

Appropriate	e engineering
	controls

General exhaust is adequate under normal operating conditions.

Individual protection measures, such as personal protective equipment













None under normal operating conditions.

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: **06/12/2024**Print Date: **06/18/2024**

	DTHERWISE: Safety glasses with side shields. Chemical goggles. [AS/NZS 1337.1, EN166 or national equivalent] Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lenses or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59].
Skin protection	See Hand protection below
Hands/feet protection	None under normal operating conditions. OTHERWISE: Wear chemical protective gloves, e.g. PVC. Wear safety footwear or safety gumboots, e.g. Rubber NOTE: The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact. Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.
Body protection	See Other protection below
Other protection	No special equipment needed when handling small quantities otherwise use • Overalls. • P.V.C apron. • Barrier cream. • Skin cleansing cream. • Eye wash unit.

Respiratory protection

Type -P Filter of sufficient capacity. (AS/NZS 1716 & 1715, EN 143:2000 & 149:2001, ANSI Z88 or national equivalent)

Required Minimum Protection Factor	Half-Face Respirator	Full-Face Respirator	Powered Air Respirator
up to 10 x ES	P1 Air-line*	-	PAPR-P1
up to 50 x ES	Air-line**	P2	PAPR-P2
up to 100 x ES	-	P3	-
		Air-line*	-
100+ x ES	-	Air-line**	PAPR-P3

* - Negative pressure demand ** - Continuous flow

A(All classes) = Organic vapours, B AUS or B1 = Acid gasses, B2 = Acid gas or hydrogen cyanide(HCN), B3 = Acid gas or hydrogen cyanide(HCN), E = Sulfur dioxide(SO2), G = Agricultural chemicals, K = Ammonia(NH3), Hg = Mercury, NO = Oxides of nitrogen, MB = Methyl bromide, AX = Low boiling point organic compounds(below 65 degC)

- · Respirators may be necessary when engineering and administrative controls do not adequately prevent exposures.
- The decision to use respiratory protection should be based on professional judgment that takes into account toxicity information, exposure measurement data, and frequency and likelihood of the worker's exposure ensure users are not subject to high thermal loads which may result in heat stress or distress due to personal protective equipment (powered, positive flow, full face apparatus may be an option).
- · Published occupational exposure limits, where they exist, will assist in determining the adequacy of the selected respiratory protection. These may be government mandated or vendor recommended.
- · Certified respirators will be useful for protecting workers from inhalation of particulates when properly selected and fit tested as part of a complete respiratory protection
- · Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU)
- · Use approved positive flow mask if significant quantities of dust becomes airborne.
- · Try to avoid creating dust conditions.

SECTION 9 Physical and chemical properties

nformation on basic physical	and chemical properties		
Appearance	A solid shaped battery; does not mix with wate	r.	
Physical state	Solid	Relative density (Water = 1)	Not Available
Odour	Not Available	Partition coefficient n-octanol / water	Not Available
Odour threshold	Not Available	Auto-ignition temperature (°C)	Not Available
pH (as supplied)	Not Available	Decomposition temperature (°C)	Not Available
Melting point / freezing point (°C)	Not Available	Viscosity (cSt)	Not Available
Initial boiling point and boiling range (°C)	Not Available	Molecular weight (g/mol)	Not Applicable
Flash point (°C)	Not Available	Taste	Not Available
Evaporation rate	Not Available	Explosive properties	Not Available
Flammability	Not Available	Oxidising properties	Not Available
Upper Explosive Limit (%)	Not Available	Surface Tension (dyn/cm or mN/m)	Not Applicable
Lower Explosive Limit (%)	Not Available	Volatile Component (%vol)	Not Available
Vapour pressure (kPa)	Not Available	Gas group	Not Available

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

Solubility in water	Immiscible	pH as a solution (1%)	Not Available
Vapour density (Air = 1)	Not Available	VOC g/L	Not Available

SECTION 10 Stability and reactivity

Reactivity	See section 7
Chemical stability	
Possibility of hazardous reactions	See section 7
Conditions to avoid	See section 7
Incompatible materials	See section 7
Hazardous decomposition products	See section 5

SECTION 11 Toxicological information

Information on toxicological effects

Inhaled	Inhalation of vapors or fumes released due to heat or a large number of leaking batteries may cause respiratory and eye irritation. Not normally a hazard due to physical form of product.		
Ingestion	Contents of a cell if opened destructively or leaking may be harmful if swallowed. Not normally a hazard due to physical form of product. Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.		
Skin Contact	Contact with battery contents will cause irritation. A shorted lithium battery can cause thermal and chemical burns upon contact with skin. Not normally a hazard due to physical form of product.		
Eye	Contact with battery contents will cause irritation. Not normally a hazard due to physical form of product.		
	The chemicals in this product are contained in a sealed can and exposure does not occur during normal handling and use. Overexposure can cause symptoms of non-fibrotic lung injury and membrane irritation. [Manufacturer]		

can cause symptoms of non-fibrotic lung injury and membrane irritation. [Manufacturer]
Repeated or prolonged exposure to corrosives may result in the erosion of teeth, inflammatory and ulcerative changes in the mouth and necrosis (rarely) of the jaw. Bronchial irritation, with cough, and frequent attacks of bronchial pneumonia may ensue. Gastrointestinal

disturbances may also occur. Chronic exposures may result in dermatitis and/or conjunctivitis.

Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems.

Practical experience shows that skin contact with the material is capable either of inducing a sensitisation reaction in a substantial number of individuals, and/or of producing a positive response in experimental animals.

Substances that can cause occupational asthma (also known as asthmagens and respiratory sensitisers) can induce a state of specific airway hyper-responsiveness via an immunological, irritant or other mechanism. Once the airways have become hyper-responsive, further exposure to the substance, sometimes even to tiny quantities, may cause respiratory symptoms. These symptoms can range in severity from a runny nose to asthma. Not all workers who are exposed to a sensitiser will become hyper-responsive and it is impossible to identify in advance who are likely to become hyper-responsive.

Chronic

Substances than can cuase occupational asthma should be distinguished from substances which may trigger the symptoms of asthma in people with pre-existing air-way hyper-responsiveness. The latter substances are not classified as asthmagens or respiratory sensitisers Wherever it is reasonably practicable, exposure to substances that can cuase occupational asthma should be prevented. Where this is not possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.

possible the primary aim is to apply adequate standards of control to prevent workers from becoming hyper-responsive.

Activities giving rise to short-term peak concentrations should receive particular attention when risk management is being considered. Health surveillance is appropriate for all employees exposed or liable to be exposed to a substance which may cause occupational asthma and there should be appropriate consultation with an occupational health professional over the degree of risk and level of surveillance.

Toxic: danger of serious damage to health by prolonged exposure through inhalation, in contact with skin and if swallowed.

Serious damage (clear functional disturbance or morphological change which may have toxicological significance) is likely to be caused by repeated or prolonged exposure. As a rule the material produces, or contains a substance which produces severe lesions. Such damage may become apparent following direct application in subchronic (90 day) toxicity studies or following sub-acute (28 day) or chronic (two-year) toxicity tests.

Exposure to the material may cause concerns for human fertility, generally on the basis that results in animal studies provide sufficient evidence to cause a strong suspicion of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects, but which are not a secondary non-specific consequence of other toxic effects.

Exposure to the material may cause concerns for humans owing to possible developmental toxic effects, generally on the basis that results in appropriate animal studies provide strong suspicion of developmental toxicity in the absence of signs of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not a secondary non-specific consequence of other toxic effects. On the basis, primarily, of animal experiments, concern has been expressed that the material may produce carcinogenic or mutagenic effects; in respect of the available information, however, there presently exists inadequate data for making a satisfactory assessment.

Lithium-Ion Battery Packs (less than or equal to 100	TOXICITY	IRRITATION	
Watt Hours) (NZ)	Not Available	Not Available	
copper	тохісіту	IRRITATION	
	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye: no adverse effect observed (not irritating) ^[1]	
	Inhalation (Rat) LC50: 0.733 mg/l4h ^[1]	Skin: no adverse effect observed (not irritating) ^[1]	
	Oral (Mouse) LD50; 0.7 mg/kg ^[2]		
Stainless Steel	тохісіту	IRRITATION	
	Not Available	Not Available	
	тохісіту	IRRITATION	
aluminium	Inhalation (Rat) LC50: >2.3 mg/l4h ^[1]	Eye: no adverse effect observed (not irritating) ^[1]	
	Oral (Rat) LD50: >2000 mg/kg ^[1]	Skin: no adverse effect observed (not irritating) ^[1]	
lithium manganate	TOXICITY	IRRITATION	

Chemwatch: 5670-40 Page 8 of 16 Issue Date: 06/12/2024 Version No. 3.1 Print Date: 06/18/2024

	Not Available	Not Available
	TOXICITY	IRRITATION
	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye: no adverse effect observed (not irritating) ^[1]
lithium cobaltate	Inhalation (Rat) LC50: 5.05 mg/l4h ^[1]	Skin: no adverse effect observed (not irritating) ^[1]
	Oral (Rat) LD50: >5000 mg/kg ^[1]	
lithium nickel manganese	TOXICITY	IRRITATION
cobalt oxide	Not Available	Not Available
	TOXICITY	IRRITATION
lithium nickel cobalt	dermal (rat) LD50: >2000 mg/kg ^[1]	Eye: adverse effect observed (irritating) ^[1]
aluminium oxide	Inhalation (Rat) LC50: 0.15 mg/l4h ^[1]	Skin: adverse effect observed (corrosive) ^[1]
	Oral (Rat) LD50: >2000 mg/kg ^[1]	
	TOXICITY	IRRITATION
nickel	Oral (Rat) LD50: 5000 mg/kg ^[2]	Not Available
	TOXICITY	IRRITATION

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Legend:

COPPER

1. Value obtained from Europe ECHA Registered Substances - Acute toxicity 2. Value obtained from manufacturer's SDS. Unless otherwise specified data extracted from RTECS - Register of Toxic Effect of chemical Substances

Skin: adverse effect observed (corrosive)[1]

WARNING: Inhalation of high concentrations of copper fume may cause "metal fume fever", an acute industrial disease of short duration. Symptoms are tiredness, influenza like respiratory tract irritation with fever. for copper and its compounds (typically copper chloride):

Acute toxicity: There are no reliable acute oral toxicity results available. In an acute dermal toxicity study (OECD TG 402), one group of 5 male rats and 5 groups of 5 female rats received doses of 1000, 1500 and 2000 mg/kg bw via dermal application for 24 hours. The LD50 values of copper monochloride were 2,000 mg/kg bw or greater for male (no deaths observed) and 1,224 mg/kg bw for female. Four females died at both 1500 and 2000 mg/kg bw, and one at 1,000 mg/kg bw. Symptom of the hardness of skin, an exudation of hardness site, the formation of scar and reddish changes were observed on application sites in all treated animals. Skin inflammation and injury were also noted. In addition, a reddish or black urine was observed in females at 2,000, 1,500 and 1,000 mg/kg bw. Female rats appeared to be more sensitive than male based on mortality and clinical signs.

No reliable skin/eye irritation studies were available. The acute dermal study with copper monochloride suggests that it has a potential to cause skin irritation

Repeat dose toxicity: In repeated dose toxicity study performed according to OECD TG 422, copper monochloride was given orally (gavage) to Sprague-Dawley rats for 30 days to males and for 39 - 51 days to females at concentrations of 0, 1.3, 5.0, 20, and 80 mg/kg bw/day. The NOAEL value was 5 and 1.3 mg/kg bw/day for male and female rats, respectively. No deaths were observed in male rats. One treatment-related death was observed in female rats in the high dose group. Erythropoietic toxicity (anaemia) was seen in both sexes at the 80 mg/kg bw/day. The frequency of squamous cell hyperplasia of the forestomach was increased in a dose-dependent manner in male and female rats at all treatment groups, and was statistically significant in males at doses of =20 mg/kg bw/day and in females at doses of =5 mg/kg bw/day doses. The observed effects are considered to be local, non-systemic effect on the forestomach which result from oral (gavage) administration of copper monochloride.

Genotoxicity: An in vitro genotoxicity study with copper monochloride showed negative results in a bacterial reverse mutation test with Salmonella typhimurium strains (TA 98, TA 100, TA 1535, and TA 1537) with and without S9 mix at concentrations of up to 1,000 ug/plate. An in vitro test for chromosome aberration in Chinese hamster lung (CHL) cells showed that copper monochloride induced structural and numerical aberrations at the concentration of 50, 70 and 100 ug/mL without S9 mix. In the presence of the metabolic activation system, significant increases of structural aberrations were observed at 50 and 70 ug/mL and significant increases of numerical aberrations were observed at 70 ug/mL. In an in vivo mammalian erythrocyte micronucleus assay, all animals dosed (15 - 60 mg/kg bw) with copper monochloride exhibited similar PCE/(PCE+NCE) ratios and MNPCE frequencies compared to those of the negative control animals. Therefore copper monochloride is not an in vivo mutagen.

Carcinogenicity: there was insufficient information to evaluate the carcinogenic activity of copper monochloride. Reproductive and developmental toxicity: In the combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD TG 422), copper monochloride was given orally (gavage) to Sprague-Dawley rats for 30 days to males and for 39-51 days to females at concentrations of 0, 1.3, 5.0, 20, and 80 mg/kg bw/day. The NOAEL of copper monochloride for fertility toxicity was 80 mg/kg bw/day for the parental animals. No treatment-related effects were observed on the reproductive organs and the fertility parameters assessed. For developmental toxicity the NOAEL was 20 mg/kg bw/day. Three of 120 pups appeared to have icterus at birth; 4 of 120 pups appeared runted at the highest dose tested (80 mg/kg bw/day).

STAINLESS STEEL

For chrome(III) and other valence states (except hexavalent):

For inhalation exposure, all trivalent and other chromium compounds are treated as particulates, not gases. The mechanisms of chromium toxicity are very complex, and although many studies on chromium are available, there is a great deal of

uncertainty about how chromium exerts its toxic influence. Much more is known about the mechanisms of hexavalent chromium toxicity than trivalent chromium toxicity. There is an abundance of information available on the carcinogenic potential of chromium compounds and on the genotoxicity and mutagenicity of chromium compounds in experimental systems. The consensus from various reviews and agencies is that evidence of carcinogenicity of elemental, divalent, or trivalent chromium compounds is lacking. Epidemiological studies of workers in a number of industries (chromate production, chromate pigment production and use, and chrome plating) conclude that while occupational exposure to hexavalent chromium compounds is associated with an increased risk of respiratory system cancers (primarily bronchogenic and nasal), results from occupational exposure studies to mixtures that were mainly elemental and trivalent (ferrochromium alloy worker) were inconclusive. Studies in leather tanners, who were exposed to trivalent chromium were consistently negative. In addition to the lack of direct evidence of carcinogenicity of trivalent or elemental chromium and its compounds, the genotoxic evidence is overwhelmingly negative. The lesser potency of trivalent chromium relative to hexavalent chromium is likely related to the higher redox potential of hexavalent chromium and its greater ability to enter cells. enter cells

The general inability of trivalent chromium to traverse membranes and thus be absorbed or reach peripheral tissue in significant amounts is generally accepted as a probable explanation for the overall absence of systemic trivalent chromium toxicity. Elemental and divalent forms of chromium are not able to traverse membranes readily either. This is not to say that elemental, divalent, or trivalent chromium compounds cannot traverse membranes and reach peripheral tissue, the mechanism of absorption is simply less efficient in comparison to absorption of hexavalent chromium compounds. Hexavalent chromium compounds exist as tetrahedral chromate anions, resembling the forms of other natural anions like sulfate and phosphate which are permeable across nonselective membranes. Trivalent chromium forms octahedral complexes which cannot easily enter though these channels, instead being absorbed via passive diffusion and phagocytosis. Although

Chemwatch: 5670-40 Page 9 of 16 Issue Date: 06/12/2024

Version No: 3.1 Print Date: 06/18/2024

Lithium-lon Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Print Date: 06/18/2024

trivalent chromium is less well absorbed than hexavalent chromium, workers exposed to trivalent compounds have had detectable levels of chromium in the urine at the end of a workday. Absorbed chromium is widely distributed throughout the body via the bloodstream, and can reach the foetus. Although there is ample in vivo evidence that hexavalent chromium is efficiently reduced to trivalent chromium in the gastrointestinal tract and can be reduced to the trivalent form by ascorbate and glutathione in the lungs, there is no evidence that trivalent chromium is converted to hexavalent chromium in biological systems. In general, trivalent chromium compounds are cleared rapidly from the blood and more slowly from the tissues. Although not fully characterized, the biologically active trivalent chromium molecule appears to be chromodulin, also referred to as (GTF). Chromodulin is an oligopeptide complex containing four chromic ions. Chromodulin may facilitate interactions of insulin with its receptor site, influencing protein, glucose, and lipid metabolism. Inorganic trivalent chromium compounds, which do not appear to have insulin-potentiating properties, are capable of being converted into biologically active forms by humans and animals

Chromium can be a potent sensitiser in a small minority of humans, both from dermal and inhalation exposures.

The most sensitive endpoint identified in animal studies of acute exposure to trivalent chromium appears to involve the respiratory system. Specifically, acute exposure to trivalent chromium is associated with impaired lung function and lung damage.

Based on what is known about absorption of chromium in the human body, its potential mechanism of action in cells, and occupational data indicating that valence states other than hexavalent exhibit a relative lack of toxicity the toxicity of elemental and divalent chromium compounds is expected to be similar to or less than common trivalent forms.

LITHIUM COBALTATE

Allergic reactions which develop in the respiratory passages as bronchial asthma or rhinoconjunctivitis, are mostly the result of reactions of the allergen with specific antibodies of the IgE class and belong in their reaction rates to the manifestation of the immediate type. In addition to the allergen-specific potential for causing respiratory sensitisation, the amount of the allergen, the exposure period and the genetically determined disposition of the exposed person are likely to be decisive. Factors which increase the sensitivity of the mucosa may play a role in predisposing a person to allergy. They may be genetically determined or acquired, for example, during infections or exposure to irritant substances. Immunologically the low molecular weight substances become complete allergens in the organism either by binding to peptides or proteins (haptens) or after metabolism (prohaptens).

Particular attention is drawn to so-called atopic diathesis which is characterised by an increased susceptibility to allergic rhinitis, allergic bronchial asthma and atopic eczema (neurodermatitis) which is associated with increased IgE synthesis.

Exogenous allergic alveolitis is induced essentially by allergen specific immune-complexes of the IgG type; cell-mediated reactions (T lymphocytes) may be involved. Such allergy is of the delayed type with onset up to four hours following exposure.

LITHIUM NICKEL COBALT ALUMINIUM OXIDE

For aluminium compounds:

Aluminium present in food and drinking water is poorly absorbed through the gastrointestinal tract. The bioavailability of aluminium is dependent on the form in which it is ingested and the presence of dietary constituents with which the metal cation can complex Ligands in food can have a marked effect on absorption of aluminium, as they can either enhance uptake by forming absorbable (usually water soluble) complexes (e.g., with carboxylic acids such as citric and lactic), or reduce it by forming insoluble compounds (e.g., with phosphate or dissolved silicate).

Considering the available human and animal data it is likely that the oral absorption of aluminium can vary 10-fold based on chemical form alone. Although bioavailability appears to generally parallel water solubility, insufficient data are available to directly extrapolate from solubility in water to bioavailability.

For oral intake from food, the European Food Safety Authority (EFSA) has derived a tolerable weekly intake (TWI) of 1 milligram (mg) of aluminium per kilogram of bodyweight. In its health assessment, the EFSA states a medium bioavailability of 0.1 % for all aluminium compounds which are ingested with food. This corresponds to a systemically available tolerable daily dose of 0.143 microgrammes (µg) per kilogramme (kg) of body weight. This means that for an adult weighing 60 kg, a systemically available dose of 8.6 µg per day is considered safe

Based on a neuro-developmental toxicity study of aluminium citrate administered via drinking water to rats, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) established a Provisional Tolerable Weekly Intake (PTWI) of 2 mg/kg bw (expressed as aluminium) for all aluminium compounds in food, including food additives. The Committee on Toxicity of chemicals in food, consumer products and the environment (COT) considers that the derivation of this PTWI was sound and that it should be used in assessing potential risks from dietary exposure to aluminium.

The Federal Institute for Risk Assessment (BfR) of Germany has assessed the estimated aluminium absorption from antiperspirants. For this purpose, the data, derived from experimental studies, on dermal absorption of aluminium from antiperspirants for healthy and damaged skin was used as a basis. At about 10.5 µg, the calculated systemic intake values for healthy skin are above the 8.6 µg per day that are considered safe for an adult weighing 60 kg. If aluminium -containing antiperspirants are used on a daily basis, the tolerable weekly intake determined by the EFSA is therefore exceeded. The values for damaged skin, for example injuries from shaving, are many times higher. This means that in case of daily use of an aluminium-containing antiperspirant alone, the TWI may be completely exhausted. In addition, further aluminium absorption sources such as food, cooking utensils and other cosmetic products must be taken into account Systemic toxicity after repeated exposure

No studies were located regarding dermal effects in animals following intermediate or chronic-duration dermal exposure to various forms of aluminium.

When orally administered to rats, aluminium compounds (including aluminium nitrate, aluminium sulfate and potassium aluminium sulfate) have produced various effects, including decreased gain in body weight and mild histopathological changes in the spleen, kidney and liver of rats (104 mg Al/kg bw/day) and dogs (88-93 mg Al/kg bw/day) during subchronic oral exposure. Effects on nerve cells, testes, bone and stomach have been reported at higher doses. Severity of effects increased with dose.

The main toxic effects of aluminium that have been observed in experimental animals are neurotoxicity and nephrotoxicity. Neurotoxicity has also been described in patients dialysed with water containing high concentrations of aluminium, but epidemiological data on possible adverse effects in humans at lower exposures are inconsistent

Reproductive and developmental toxicity:

Studies of reproductive toxicity in male mice (intraperitoneal or subcutaneous administration of aluminium nitrate or chloride) and rabbits (administration of aluminium chloride by gavage) have demonstrated the ability of aluminium to cause testicular toxicity, decreased sperm quality in mice and rabbits and reduced fertility in mice. No reproductive toxicity was seen in females given aluminium nitrate by gavage or dissolved in drinking water. Multi-generation reproductive studies in which aluminium sulfate and aluminium ammonium sulfate were administered to rats in drinking water, showed no evidence of reproductive toxicity

High doses of aluminium compounds given by gavage have induced signs of embryotoxicity in mice and rats in particular, reduced fetal body weight or pup weight at birth and delayed ossification. Developmental toxicity studies in which aluminium chloride was administered by gavage to pregnant rats showed evidence of foetotoxicity, but it was unclear whether the findings were secondary to maternal toxicity. A twelve-month neuro-development with aluminium citrate administered via the drinking water to Sprague-Dawley rats, was conducted according to Good Laboratory Practice (GLP). Aluminium citrate was selected for the study since it is the most soluble and bioavailable aluminium salt. Pregnant rats were exposed to aluminium citrate from gestational day 6 through lactation, and then the offspring were exposed post-weaning until postnatal day 364. An extensive functional observational battery of tests was performed at various times. Evidence of aluminium toxicity was demonstrated in the high (300 mg/kg bw/day of aluminium) and to a lesser extent, the mid-dose groups (100 mg/kg bw/day of aluminium). In the high-dose group, the main effect was renal damage, resulting in high mortality in the male offspring. No major neurological pathology or neurobehavioural effects were observed, other than in the neuromuscular subdomain (reduced grip strength and increased foot splay). Thus, the lowest observed adverse effect level (LOAEL) was 100 mg/kg bw/day and the no observed adverse effect level (NOAEL) was 30 mg/kg bw/day. Bioavailability of aluminium chloride, sulfate and nitrate and aluminium hydroxide was much lower than that of aluminium citrate This study was used by JECFA as key study to derive the PTWI.

Aluminium compounds were non-mutagenic in bacterial and mammalian cell systems, but some produced DNA damage and effects on chromosome integrity and segregation in vitro. Clastogenic effects were also observed in vivo when aluminium sulfate was administered at high doses by gavage or by the intraperitoneal route. Several indirect mechanisms have been proposed to explain the variety of genotoxic effects elicited by aluminium salts in experimental systems. Cross-linking of DNA with chromosomal proteins, interaction with microtubule assembly and mitotic spindle functioning, induction of oxidative damage, damage of lysosomal membranes with liberation of DNAase, have been suggested to explain the induction of structural chromosomal aberrations, sister chromatid exchanges, chromosome loss and formation of oxidized bases in experimental systems. The EFSA Panel noted that these indirect mechanisms of genotoxicity, occurring at relatively high levels of exposure, are unlikely to be of relevance for humans exposed to aluminium via the diet. Aluminium compounds do not cause gene mutations in either bacteria or mammalian cells. Exposure to aluminium compounds does result in both structural and numerical

Chemwatch: 5670-40 Page 10 of 16 Issue Date: 06/12/2024 Print Date: 06/18/2024

Version No: 3.1 Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

> chromosome aberrations both in in-vitro and in-vivo mutagenicity tests. DNA damage is probably the result of indirect mechanisms. The DNA damage was observed only at high exposure levels.

Carcinogenicity

The available epidemiological studies provide limited evidence that certain exposures in the aluminium production industry are carcinogenic to humans, giving rise to cancer of the lung and bladder. However, the aluminium exposure was confounded by exposure to other agents including polycyclic aromatic hydrocarbons, aromatic amines, nitro compounds and asbestos. There is no evidence of increased cancer risk in non-occupationally exposed persons.

Neurodegenerative diseases.

Following the observation that high levels of aluminium in dialysis fluid could cause a form of dementia in dialysis patients, a number of studies were carried out to determine if aluminium could cause dementia or cognitive impairment as a consequence of environmental exposure over long periods. Aluminium was identified, along with other elements, in the amyloid plaques that are one of the diagnostic lesions in the brain for Alzheimer disease, a common form of senile and pre-senile dementia, some of the epidemiology studies suggest the possibility of an association of Alzheimer disease with aluminium in water, but other studies do not confirm this association. All studies lack information on ingestion of aluminium from food and how concentrations of aluminium in food affect the association between aluminium in water and Alzheimer disease." There are suggestions that persons with some genetic variants may absorb more aluminium than others, but there is a need for more analytical research to determine whether aluminium from various sources has a significant causal association with Alzheimer disease and other neurodegenerative diseases. Aluminium is a neurotoxicant in experimental animals. However, most of the animal studies performed have several limitations and therefore cannot be used for quantitative risk assessment. Contact sensitivity:

It has been suggested that the body burden of aluminium may be linked to different iseases. Macrophagic myofasciitis and chronic fatigue syndrome can be caused by aluminium-containing adjuvants in vaccines. Macrophagic myofasciitis (MMF) has been described as a disease in adults presenting with ascending myalgia and severe fatigue following exposure to aluminium hydroxide-containing vaccines The corresponding histological findings include aluminium-containing macrophages infiltrating muscle tissue at the injection site. The hypothesis is that the long-lasting granuloma triggers the development of the systemic syndrome.

Aluminium acts not only as an adjuvant, stimulating the immune system either to fend off infections or to tolerate antigens, it also acts as a sensitisers causing contact allergy and allergic contact dermatitis. In general, metal allergies are very common and aluminium is considered to be a weak allergen. A metal must be ionised to be able to act as a contact allergen, then it has to undergo haptenisation to be immunogenic and to initiate an immune response. Once inside the skin, the metal ions must bind to proteins to become immunologically reactive. The most important routes of exposure and sensitisation to aluminium are through aluminium-containing vaccines. One Swedish study showed a statistically significant association between contact allergy to aluminium and persistent itching nodules in children treated with allergen-specific immunotherapy (ASIT) Nodules were overrepresented in patients with contact allergy to aluminium Other routes of sensitisation reported in the literature are the prolonged use of aluminium-containing antiperspirants, topical medication, and tattooing of the skin with aluminium-containing pigments. Most of the patients experienced eczematous reactions whereas tattooing caused granulomas. Even though aluminium is used extensively in industry, only a low number of cases of occupational skin sensitisation to aluminium have been reported Systemic allergic contact dermatitis in the form of flare-up reactions after re-exposure to aluminium has been documented: pruritic nodules at present and previous injection sites, eczema at the site of vaccination as well as at typically atopic localisations after vaccination with aluminium-containing vaccines and/or patch testing with aluminium, and also after use of aluminiumcontaining toothpaste

Oral (rat) TDLo: 500 mg/kg/5D-I Inhalation (rat) TCLo: 0.1 mg/m3/24H/17W-C

NICKEL WARNING: This substance has been classified by the IARC as Group 2B: Possibly Carcinogenic to Humans. Tenth Annual Report on Carcinogens: Substance anticipated to be Carcinogen

[National Toxicology Program: U.S. Dep. of Health & Human Services 2002]

COPPER & STAINLESS STEEL & LITHIUM **COBALTATE & LITHIUM** NICKEL MANGANESE **COBALT OXIDE & LITHIUM** NICKEL COBALT ALUMINIUM **OXIDE & NICKEL**

The following information refers to contact allergens as a group and may not be specific to this product. Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke's oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

STAINLESS STEEL & LITHIUM **FLUOROPHOSPHATE**

STAINLESS STEEL &

Asthma-like symptoms may continue for months or even years after exposure to the material ends. This may be due to a non-allergic condition known as reactive airways dysfunction syndrome (RADS) which can occur after exposure to high levels of highly irritating compound. Main criteria for diagnosing RADS include the absence of previous airways disease in a non-atopic individual, with sudden onset of persistent asthma-like symptoms within minutes to hours of a documented exposure to the irritant. Other criteria for diagnosis of RADS include a reversible airflow pattern on lung function tests, moderate to severe bronchial hyperreactivity on methacholine challenge testing, and the lack of minimal lymphocytic inflammation, without eosinophilia. RADS (or asthma) following an irritating inhalation is an infrequent disorder with rates related to the concentration of and duration of exposure to the irritating substance. On the other hand, industrial bronchitis is a disorder that occurs as a result of exposure due to high concentrations of irritating substance (often particles) and is completely reversible after exposure ceases. The disorder is characterized by difficulty breathing, cough and mucus production.

ALUMINIUM & LITHIUM MANGANATE & LITHIUM COBALTATE & LITHIUM NICKEL MANGANESE COBALT OXIDE & LITHIUM NICKEL COBALT ALUMINIUM **OXIDE & LITHIUM FLUOROPHOSPHATE**

No significant acute toxicological data identified in literature search.

LITHIUM COBALTATE & LITHIUM NICKEL MANGANESE COBALT OXIDE & LITHIUM NICKEL **COBALT ALUMINIUM OXIDE**

Goitrogenic:.

Goitrogens are substances that suppress the function of the thyroid gland by interfering with iodine uptake, which can, as a result, cause an enlargement of the thyroid, i.e., a goitre

Goitrogens include:

- Vitexin, a flavanoid, which inhibits thyroid peroxidase thus contributing to goiter.
- lons such as thiocyanate and perchlorate which decrease iodide uptake by competitive inhibition; as a consequence of reduced thyroxine and triiodothyronine secretion by the gland, at low doses, this causes an increased release of thyrotropin (by reduced negative feedback), which then stimulates the gland.
- Lithium which inhibits thyroid hormone release.
- Certain foods, such as soy and millet (containing vitexins) and vegetables in the genus Brassica (e.g. broccoli, brussels sprouts, cabbage, horseradish).
- Caffeine (in coffee, tea, cola, chocolate) which acts on thyroid function as a suppressant.

Acute Toxicity	~	Carcinogenicity	~
Skin Irritation/Corrosion	✓	Reproductivity	✓
Serious Eye Damage/Irritation	✓	STOT - Single Exposure	*
Respiratory or Skin sensitisation	~	STOT - Repeated Exposure	~

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: **06/12/2024**Print Date: **06/18/2024**

Mutagenicity Aspiration Hazard

Legend:

X − Data either not available or does not fill the criteria for classification

→ − Data available to make classification

SECTION 12 Ecological information

Tox	

Lithium-Ion Battery Packs	Endpoint	Test Duration (hr)	Species	Value	Source
(less than or equal to 100 Watt Hours) (NZ)	Not Available	Not Available	Not Available	Not Available	Not Availab
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	48h	Fish	<0.001mg/L	4
	EC50	72h	Algae or other aquatic plants	0.011- 0.017mg/L	4
copper	EC50	96h	Algae or other aquatic plants	0.03- 0.058mg/l	4
	EC50	48h	Crustacea	<0.001mg/L	4
	LC50	96h	Fish	0.003mg/L	2
	Endpoint	Test Duration (hr)	Species	Value	Source
Stainless Steel	Not Available	Not Available	Not Available	Not Available	Not Availab
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	72h	Algae or other aquatic plants	>100mg/l	1
	EC50	72h	Algae or other aquatic plants	0.017mg/L	2
aluminium	EC50	96h	Algae or other aquatic plants	0.005mg/L	2
	EC50	48h	Crustacea	0.736mg/L	2
	LOFO	96h	Field	0.078-	2
	LC50	9011	FISH	0.108mg/l	
	Endpoint	Test Duration (hr)	Species	Value	Source
lithium manganate	Not Available	Not Available	Not Available	Not Available	Not Availab
	Endpoint	Test Duration (hr)	Species	Value	Source
	LC50	96h	Fish	0.8mg/l	2
124 2	EC50	72h	Algae or other aquatic plants	0.029mg/L	2
lithium cobaltate	EC50	48h	Crustacea	acea 0.241mg/L	
	EC10(ECx)	168h	Crustacea	0.001mg/L	2
	EC50	96h	Algae or other aquatic plants	Algae or other aquatic plants 23.8mg/l	
ishin miakal manganaa	Endpoint	Test Duration (hr)	Species	Value	Source
lithium nickel manganese cobalt oxide	Not Available	Not Available	Not Available	Not Available	Not Availab
	Endpoint	Test Duration (hr)	Species	Value	Source
lithium nickel cobalt aluminium oxide	EC50	72h	Algae or other aquatic plants	>1mg/l	2
alullilliulli Oxide	NOEC(ECx)	672h	Fish	>0.1<=1mg/l	2
	Endpoint	Test Duration (hr)	Species	Value	Source
	EC50(ECx)	72h	Algae or other aquatic plants	0.18mg/l	1
	EC50	72h	Algae or other aquatic plants	0.18mg/l	1
nickel	EC50	96h	Algae or other aquatic plants	0.174- 0.311mg/L	4
	EC50	48h	Crustacea	>100mg/l	1
	LC50	96h	Fish	0.06mg/L	4
	Endpoint	Test Duration (hr)	Species	Value	Source
	NOEC(ECx)	528h	Fish	0.2mg/l	2
lithium fluoranhaanhata	EC50	72h	Algae or other aquatic plants	62mg/l	2
lithium fluorophosphate	LC50	96h	Fish	42mg/l	2
	EC50	96h	Algae or other aquatic plants	43mg/l	2
	EC50	48h	Crustacea	98mg/l	2
Legend:	Extracted from Ecotox databas	IUCLID Toxicity Data 2. Europe E	Crustacea CHA Registered Substances - Ecotoxicological Inform C Aquatic Hazard Assessment Data 6. NITE (Japan) -	nation - Aquatic Toxicity	4. US

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

DO NOT discharge into sewer or waterways.

Persistence and degradability

Ingredient	Persistence: Water/Soil	Persistence: Air	
	No Data available for all ingredients	No Data available for all ingredients	

Bioaccumulative potential

	ioaccumulation
No I	U Dala available iui ali liluleuletiis

Mobility in soil

Ingredient	Mobility		
	No Data available for all ingredients		

SECTION 13 Disposal considerations

Waste treatment methods

Product / Packaging disposal

- Recycle wherever possible or consult manufacturer for recycling options.
 Consult State Land Waste Management Authority for disposal.
 Bury residue in an authorised landfill.

- Recycle containers if possible, or dispose of in an authorised landfill.

SECTION 14 Transport information

Labels Required



Marine Pollutant



HAZCHEM 2Y

Land transport (ADG)

14.1. UN number or ID number	3481				
14.2. UN proper shipping name	LITHIUM ION BATTERIES CONTAINED IN EQUIPMENT or LITHIUM ION BATTERIES PACKED WITH EQUIPMENT (including lithium ion polymer batteries)				
14.3. Transport hazard class(es)	Class Subsidiary Hazard				
14.4. Packing group	Not Applicable				
14.5. Environmental hazard	Environmentally hazardous				
14.6. Special precautions for user	Special provisions 188 230 310 348 360 376 377 384 387 390 Limited quantity 0				

Air transport (ICAO-IATA / DGR)

14.1. UN number	3481			
14.2. UN proper shipping name	Lithium ion batteries contained in equipment (including lithium ion polymer batteries)			
	ICAO/IATA Class	9		
14.3. Transport hazard class(es)	ICAO / IATA Subsidiary Hazard	Not Applicable		
3.000(00)	ERG Code	12FZ		
14.4. Packing group	Not Applicable			
14.5. Environmental hazard	Environmentally hazardous			
14.6. Special precautions for user	Special provisions A48 A88 A99 A154 A164 A181 A185 A213 A220			
	Cargo Only Packing Instructions		967	
	Cargo Only Maximum Qty / Pack		35 kg	
	Passenger and Cargo Packing Instructions		967	
	Passenger and Cargo Maximum Qty / Pack		5 kg	
	Passenger and Cargo Limited Qu	uantity Packing Instructions	Forbidden	
	Passenger and Cargo Limited Ma	aximum Qty / Pack	Forbidden	

Chemwatch: 5670-40 Page 13 of 16 Version No: 3.1

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

Sea transport (IMDG-Code / GGVSee)

3481		
LITHIUM ION BATTERIES CONTAINED IN EQUIPMENT (including lithium ion polymer batteries)		
IMDG Class	9	
IMDG Subsidiary Ha	zard Not Applicable	
Not Applicable		
Marine Pollutant		
EMS Number	F-A, S-I	
Special provisions	188 230 310 348 360 376 377 384 387 390	
Limited Quantities	0	
	IMDG Class IMDG Subsidiary Ha Not Applicable Marine Pollutant EMS Number Special provisions	

14.7.1. Transport in bulk according to Annex II of MARPOL and the IBC code

Not Applicable

14.7.2. Transport in bulk in accordance with MARPOL Annex V and the IMSBC Code

Product name	Group
copper	Not Available
Stainless Steel	Not Available
aluminium	Not Available
lithium manganate	Not Available
lithium cobaltate	Not Available
lithium nickel manganese cobalt oxide	Not Available
lithium nickel cobalt aluminium oxide	Not Available
nickel	Not Available
lithium fluorophosphate	Not Available

14.7.3. Transport in bulk in accordance with the IGC Code

Product name	Ship Type
copper	Not Available
Stainless Steel	Not Available
aluminium	Not Available
lithium manganate	Not Available
lithium cobaltate	Not Available
lithium nickel manganese cobalt oxide	Not Available
lithium nickel cobalt aluminium oxide	Not Available
nickel	Not Available
lithium fluorophosphate	Not Available

SECTION 15 Regulatory information

Safety, health and environmental regulations / legislation specific for the substance or mixture

copper is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 4

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule ${\bf 5}$

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 6

Australian Inventory of Industrial Chemicals (AIIC)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

Stainless Steel is found on the following regulatory lists

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 2 $\,$

Australia Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP) - Schedule 5

Australian Inventory of Industrial Chemicals (AIIC)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

aluminium is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

lithium manganate is found on the following regulatory lists

Version No: 3.1

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: **06/12/2024**Print Date: **06/18/2024**

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

lithium cobaltate is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

lithium nickel manganese cobalt oxide is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 1: Carcinogenic to humans

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

lithium nickel cobalt aluminium oxide is found on the following regulatory lists

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 1: Carcinogenic to humans

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

nickel is found on the following regulatory lists

Australia Hazardous Chemical Information System (HCIS) - Hazardous Chemicals

Australian Inventory of Industrial Chemicals (AIIC)

Chemical Footprint Project - Chemicals of High Concern List

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs

International Agency for Research on Cancer (IARC) - Agents Classified by the IARC Monographs - Group 2B: Possibly carcinogenic to humans

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

lithium fluorophosphate is found on the following regulatory lists

Australian Inventory of Industrial Chemicals (AIIC)

International WHO List of Proposed Occupational Exposure Limit (OEL) Values for Manufactured Nanomaterials (MNMS)

Additional Regulatory Information

Not Applicable

National Inventory Status

National Inventory	Status	
Australia - AIIC / Australia Non- Industrial Use	No (lithium manganate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide)	
Canada - DSL	No (lithium manganate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide; lithium fluorophosphate)	
Canada - NDSL	No (copper; Stainless Steel; aluminium; lithium manganate; lithium cobaltate; lithium nickel manganese cobalt oxide; nickel)	
China - IECSC	No (lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide)	
Europe - EINEC / ELINCS / NLP	No (lithium manganate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide)	
Japan - ENCS	No (copper; Stainless Steel; aluminium; lithium manganate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide nickel; lithium fluorophosphate)	
Korea - KECI	No (lithium nickel manganese cobalt oxide)	
New Zealand - NZIoC	No (lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide; lithium fluorophosphate)	
Philippines - PICCS	No (Stainless Steel; lithium manganate; lithium cobaltate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide)	
USA - TSCA	No (lithium nickel manganese cobalt oxide)	
Taiwan - TCSI	Yes	
Mexico - INSQ	No (Stainless Steel; lithium manganate; lithium cobaltate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide; lithium fluorophosphate)	
Vietnam - NCI	Yes	
Russia - FBEPH	No (Stainless Steel; lithium manganate; lithium cobaltate; lithium nickel manganese cobalt oxide; lithium nickel cobalt aluminium oxide; lithium fluorophosphate)	
Legend:	Yes = All CAS declared ingredients are on the inventory No = One or more of the CAS listed ingredients are not on the inventory. These ingredients may be exempt or will require registration.	

SECTION 16 Other information

Revision Date	06/12/2024
Initial Date	11/24/2023

SDS Version Summary

Version	Date of Update	Sections Updated
3.1	06/12/2024	Hazards identification - Classification, Composition / information on ingredients - Ingredients

Other information

Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

The SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

Chemwatch: 5670-40 Page 15 of 16

Version No: 3.1

Lithium-Ion Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Issue Date: 06/12/2024 Print Date: 06/18/2024

- ▶ PC TWA: Permissible Concentration-Time Weighted Average
- ▶ PC STEL: Permissible Concentration-Short Term Exposure Limit
- IARC: International Agency for Research on Cancer
- ▶ ACGIH: American Conference of Governmental Industrial Hygienists
- ▶ STEL: Short Term Exposure Limit
- TEEL: Temporary Emergency Exposure Limit,
 IDLH: Immediately Dangerous to Life or Health Concentrations
- ES: Exposure Standard
- ▶ OSF: Odour Safety Factor
- ▶ NOAEL: No Observed Adverse Effect Level
- ► LOAEL: Lowest Observed Adverse Effect Level
- TLV: Threshold Limit Value
- LOD: Limit Of Detection
- OTV: Odour Threshold Value
- ▶ BCF: BioConcentration Factors
- ▶ BEI: Biological Exposure Index
- ▶ DNEL: Derived No-Effect Level
- ▶ PNEC: Predicted no-effect concentration
- ▶ AIIC: Australian Inventory of Industrial Chemicals
- ▶ DSL: Domestic Substances List
- ▶ NDSL: Non-Domestic Substances List
- IECSC: Inventory of Existing Chemical Substance in China
 EINECS: European INventory of Existing Commercial chemical Substances
- ► ELINCS: European List of Notified Chemical Substances
- ▶ NLP: No-Longer Polymers
- ▶ ENCS: Existing and New Chemical Substances Inventory
- KECI: Korea Existing Chemicals Inventory
 NZIoC: New Zealand Inventory of Chemicals
- ▶ PICCS: Philippine Inventory of Chemicals and Chemical Substances
- ► TSCA: Toxic Substances Control Act
- ▶ TCSI: Taiwan Chemical Substance Inventory
- ▶ INSQ: Inventario Nacional de Sustancias Químicas
- NCI: National Chemical Inventory
 FBEPH: Russian Register of Potentially Hazardous Chemical and Biological Substances

This document is copyright.

Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH.

TEL (+61 3) 9572 4700.

Chemwatch: **5670-40** Page **16** of **16**

Version No: 3.1 Lithium-lon Battery Packs (less than or equal to 100 Watt Hours) (NZ)

Page 16 of 16 Issue Date: 06/12/2024

Print Date: 06/18/2024